Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The offering resulted in approximately $143.4 million of proceeds to Applied Therapeutics, before deducting underwriting discounts and estimated offering expenses. Applied Therapeutics’ common stock is listed on the Nasdaq Global Market under the symbol “APLT.”

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. Its lead product candidate is a novel central nervous system penetrant aldose reductase inhibitor being developed for the treatment of galactosemia, a rare pediatric metabolic disease.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Alain Kuyumjian and associate Amanda Rae Schwarzenbart. Partner Michael Mollerus and associate Joseph M. Gerstel provided tax advice. The intellectual property and technology team included partner David R. Bauer and associate Yifu Chen. Counsel Loyti Cheng and associate Cristina Harshman provided environmental advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post